Cargando…
Bevacizumab in Glaucoma: Where do We Stand?
The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control tria...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Jaypee Brothers Medical Publishers
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161771/ https://www.ncbi.nlm.nih.gov/pubmed/28028350 http://dx.doi.org/10.5005/jp-journals-10008-1110 |